Back to Journals » OncoTargets and Therapy » Volume 6

Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors

Authors Li Z, Zhang X, Chen Y, Guo J, Sai K, Yang Q, Chen Z, Mou Y

Received 12 May 2013

Accepted for publication 5 June 2013

Published 10 July 2013 Volume 2013:6 Pages 869—875


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Zhen-ye Li,2 Xiang-heng Zhang,1 Yu Chen,1 Jian-gui Guo,1 Ke Sai,1 Qun-ying Yang,1 Zhong-ping Chen,1 Yong-gao Mou1

1State Key Laboratory of Oncology in South China, Department of Neurosurgery, Sun Yat-sen University Cancer Center, Guangzhou, 2Beijing Neurosurgical Institute, Capital Medical University, Beijing, People’s Republic of China

Background: B7-H4, a member of the inhibitory B7 family, is shown to have a profound inhibitory effect on the proliferation, activation, cytokine secretion, and development of cytotoxicity of T cells and may be involved in immune evasion in cancer patients. Although B7-H4 expression has been detected in non-small cell lung cancer (NSCLC), there are no published reports on the expression of B7-H4 in brain metastases from NSCLC.
Methods: We examined the expression of B7-H4 by immunohistochemistry in 49 cases of brain metastatic NSCLC, 18 cases of matched primary NSCLC, and 20 cases of NSCLC patients who had neither brain metastases nor other distant metastases.
Results: B7-H4 was highly expressed in 20 (40.8%) out of 49 brain metastases and two (11.1%) out of 18 matched primary tumors. The expression of B7-H4 in brain metastases appeared to be significantly higher than their matched primary tumors (P = 0.016). We also found that patients with high B7-H4 expression in their primary NSCLC have a higher risk of developing brain metastases (P = 0.022). Univariate analyses showed that median overall survival was significantly shorter in patients with high B7-H4 expression in brain metastases (P = 0.002). Multivariate analyses showed that B7-H4 was a significant independent prognostic indicator (P = 0.003).
Conclusion: NSCLC patients with high B7-H4 expression may benefit from aggressive treatment and close surveillance. Furthermore, our study suggests that B7-H4 may play an important role in the metastatic process of NSCLC and is promising to be a new immune checkpoint molecule for future antitumoral immunotherapy.

Keywords: B7-H4, brain metastases, non-small cell lung cancer, immunotherapy

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.